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Introduction
Glutamine is an important amino acid, which is involved in many cellular processes (Neu et al., 1996) . Glutamine is s huttled across cellular membranes by a v ariety of transport systems (Bode, 2001) . One of these systems, the neutral amino acid transporter ASCT2, was shown to belong to the solute carrier 1 family of transporters (Utsunomiya-Tate et al., 1996) . ASCT2 is specific for transporting small, neutral amino acids, such as glutamine, alanine, serine and cysteine (Bass et al., 1981; Utsunomiya-Tate et al., 1996) . In contrast to ASCT2, the closelyrelated SLC1 family member ASCT1 was shown to lack affinity for glu tamine (Arriza et al., 1993) . ASCT2 was reported to be an obligate amino acid exchanger (Broer et al., 2000) . Thus, amino acid uptake is strictly coupled to amino acid release (exchange) of an intracellular amino acid. This exchange requires the presence of Na + , since amino acid translocation is coupled to the co-translocation of at least one sodium ion (Broer et al., 2000; Grewer and Grabsch, 2004) .
In addition to the amino acid exchange function, ASCT2 displays a c hannel-like anion conductance, which depends on the presence of Na + and is amplified by binding of transported substrates and inhibited in the presence of competitive inhibitors (Broer et al., 2000; Grewer and Grabsch, 2004) .
ASCT2 is expressed in many tissues, including the brain, in which it may contribute to glutamine homeostasis of neurons and astrocytes (Broer and Brookes, 2001; Deitmer et al., 2003; Gliddon et a l., 2009) . It was hypothesized, for example, that ASCT2 mediates efflux of glutamine from astrocytes, a p rocess that is critical for the functioning of the glutamateglutamine cycle, which recycles synaptically-released glutamate. D espite this seemingly important role, the pharmacology of ASCTs is not well understood. While the specificity for a large variety of transported substrates has been studied, not much is known about inhibitors of This article has not been copyedited and formatted. The final version may differ from this version. ASCT2 amino acid transport Grewer and Grabsch, 2004) . A few inhibitors have been developed based on homology of the amino acid binding site with the related glutamate transporters from the EAAT (excitatory amino acid transporter) family (Grewer and Grabsch, 2004) . I n particular, a s eries of glutamine derivatives were developed with substituents that alter the pK a value of a proposed hydrogen bond donor in form of the amide NH bond . However, affinities were in the 500 μM to low mM range and no distinctions were made with regard to the structural properties that differentiate inhibitors from transported substrates.
Here, we aimed at performing structure function studies in order to develop inhibitors with higher binding affinity, as well as to obtain a better understanding of the molecular determinants of the compounds that differentiate blockers from transported substrates. We have used a docking approach to identify serine derivatives as potential ligands with a series of substituents attached to the hydroxyl oxygen. Experimental validation of the predicted compounds suggests that the activity of the transported substrates decreases strongly after side-chain volume reaches a threshold. In contrast, inhibitors benefit from hydrophobic bulk in the side chain, in particular when the hydrophobic group is aromatic. The analysis resulted in the development of a blocker with approximately 3-fold higher affinity than the best compounds that have been reported previously.
Materials and Methods
Cell culture and transfection. cDNA coding for the rat ASCT2 was kindly provided by S.
Bröer (Broer et al., 1999; Broer et al., 2000) . The coding region of the cDNA was subcloned into the EcoRI site of the pBK-CMV vector (Stratagene). whole-cell current-recording configuration was used (Hamill et al., 1981) . Electrode resistances were 2-3 MΩ, the series resistance was 5-8 MΩ. Series resistance (R S ), was not compensated, as compensation had no effect on th e magnitude of the observed currents. The extracellular bath solution contained (in m M): 140 NaOMs or N aSCN, 2 Mg (GlcA) 2 , 2 Ca(GlcA) 2 , and 10 HEPES (pH 7.4 / NaOH). The pipette solution contained (in mM): 130 NaSCN, 2 MgCl 2 , 10 EGTA, 10 H EPES, and 10 L-alanine (pH 7.3 / NaOH). Us ing this intracellular solution, the transporters are operated in th e exchange mode, in w hich external alanine is exchanged with internal alanine in the absence of net transport. The exchange mode is associated with the activation of an uncoupled anion current, which was used as an assay for ASCT2 function. The currents were low pass filtered at 3 kHz (EPC7 built-in filter) and digitized with a digitizer board (Digidata 1200, Axon Instruments, Foster City, CA, USA) at a sampling rate of 1 0-50 kHz (controlled by software, Axon PClamp7). All experiments were performed at room temperature.
Rapid solution exchange was essentially performed as described previously (Grewer et al., 2000; . Briefly, substrates and inhibitors were applied to the ASCT2-expressing HEK293 cells with a quartz tube (350 µm tube diameter) positioned at a distance of ≈ 0.5 mm to the cell. The linear flow rate of the solutions emerging from the opening of the tube was approximately 5-10 cm/s, resulting in typical rise times of the whole-cell current of 30-50 ms (10 to 90 %).
This article has not been copyedited and formatted. The final version may differ from this version. (Boudker et al., 2007) ) and PDB refcode 2NWW (inhibitor-bound, reentrant loop RL2 open,. Alignments were generated using ClustalW or HHPred (Soding et al., 2005) with similar results, due to the high sequence similarity (85%) in the substrate binding region. O utputs of the pair-wise sequence alignments were used to create structural homology models with the Modeller software (Eswar et al., 2007) . For 2NWX as the template, Modeller was programmed to include the two bound cations in the homology model. The resulting structure files were tested for quality with the ProQ program (Wallner and El ofsson, 2003) , to test for correct helical assignment of the transmembrane segments.
Docking was performed using the Autodock Vina program (Trott and Olson, 2010) , using
PyRx as the front-end for li gand preparation and positioning of th e binding box (Wolf, 2009 ).
Ligands were initially generated using ChemSketch (Advanced Chemistry Development, Inc.
(ACD/Labs)), setting the correct protonation states for p H 7.3 using Open Babel (http://openbabel.sourceforge.net/). Subsequently, ligands were imported into PyRx and energyminimized using the UFF force field. The box for docking was set as cubic, 15 Ǻ wide, and centered at the C β atom of the bound amino acid molecule.
Synthesis. All chemicals were purchased from VWR. The compounds were prepared This article has not been copyedited and formatted. The final version may differ from this version. 
Results
In silico docking studies predict open-loop or closed-loop preference of substrates and inhibitors.
In an effort to predict the s tructure of ligands that interact with the ASCT2 amino acid binding site with reasonable affinity, we used a l igand docking approach. The docking templates were homology models of ASCT2, based on the crystal structures of a n homologous archaeal aspartate transporter, Glt Ph , (Boudker et al., 2007; Yernool et al., 2004) . Although the This article has not been copyedited and formatted. The final version may differ from this version. overall identity between the ASCT2 and GltPh sequences is low (30% identity, 50% similarity), the amino acid binding site (residues in 4 Ǻ distance of the bound ligand) is very well conserved with 69% identity and 85% similarity. In fact, only two side chains that contribute to the ligand binding site are not conserved, which are C479 (corresponding to R397 in GltPh) and A402
(corresponding to T314 in GltPh). The R-C substitution in TM8 is known to be mainly responsible for the different substrate selectivities of the two transporters (Bendahan et al., 2000) . I n GltPh, the positively-charged side chain of R397 forms a s alt bridge with the β-carboxylate of aspartate (Yernool et al., 2004) . This electrostatic interaction is absent in the ASCTs, accounting for their propensity to bind neutral amino acid substrates.
In order to test the docking approach, we first performed control docking studies using the known, aspartate-bound crystal structure of Glt Ph as the template (PDB ID 2NWX, (Boudker et al., 2007) ). Docking was performed in Autodock Vina, using a 15 Overall, this analysis suggests that the docking procedure is capable of detecting physically relevant conformations of bound ligands in EAAT proteins.
We then used the docking approach to predict the interaction of neutral amino acid derivatives with ASCT2. We used two separate homology models, based on templates 2NWX, termed ASCT2(2NWX), and 2NWW, termed ASCT2(2NWW) (Boudker et al., 2007) . The former This article has not been copyedited and formatted. The final version may differ from this version. over the TBOA-bound GltPh structure, 2NWW (Boudker et al., 2007) . It is evident that the aromatic group adopts a s lightly different orientation in b enzylserine compared to TBOA, possibly due to the lack of salt-bridge interaction from the missing β-carboxylate.
As will be discussed in the next paragraphs, our experimental results demonstrate that serine with the substituent carboxylic acid using either the DCC method (Sheehan et al., 1956 ), or the acid chloride (Fig. 2) , followed by deprotection of the amino acid. The compounds were tested for their ability to either activate anion current, or inhibit leak anion current in ASCT2
heterologously expressed in HEK293 cells. I t was previously shown that the transportermediated anion current can be used as a measure of transport activity (Broer et al., 2000; Grewer and Grabsch, 2004) . This fact is also well established for the homologous glutamate transporters
This article has not been copyedited and formatted. The final version may differ from this version. , which have a m uch more rigorously determined pharmacology (Bridges and Esslinger, 2005; Bridges et al., 1999; Dunlop and Butera, 2006; Dunlop et al., 2003; Luethi et al., 2010; Shimamoto et al., 1998) . Transport current cannot be used as an assay for the function of ASCT2 substrates/inhibitors, because ASCT2 is an amino acid exchanger and, thus, no steady-state transport current can be observed (Broer et al., 2000; Zerangue and Kavanaugh, 1996) . However, our results demonstrate that inhibitors block charge movement that is induced by voltage-dependent movement of transported substrates across the membrane (not shown), suggesting that the anion current assay reflects on exchange activity.
Transported substrates are known to induce anion current when applied to ASCT2 (Broer et al., 2000; Grewer and Grabsch, 2004) , as shown in Fig. 4A for L-alanine. While acetyl serine ester (6c) was a full substrate, eliciting anion current of the same magnitude as that of alanine, the isobutyryl ester (4c) with the larger substituent volume and increased hydrophobicity was a partial substrate with 26 ± 10% of the maximal alanine-induced current (at saturating concentration, Fig. 4B , ASCT2 (up to 5 mM), indicating that this compound either does not bind to ASCT2 at the tested concentrations, or that it binds, but is not an activating substrate. The former possibility is more likely, as 1c at a concentration up to 2 mM was unable to inhibit alanine-induced inward anion currents mediated by ASCT2 alanine exchange (data not shown).
Next, we tested compounds that were predicted to be inhibitors from the docking studies. In contrast to transported substrates, inhibitor application mediated an apparent outward current in ASCT2-expressing HEK293 cells (representative original traces shown in Fig. 5A ). This
This article has not been copyedited and formatted. The final version may differ from this version. outward current was previously shown to be caused by inhibition of a leak inward anion current (Grewer and Grabsch, 2004) , in agreement with results obtained for inhibition of the homologous glutamate transporters (EAATs) by the competitive inhibitor TBOA (Grewer et al., 2005; Grewer et al., 2000) . The apparent outward current was dose dependent and could be analyzed using a Michaelis-Menten-type equation (Fig. 5B) , yielding K m values listed in table 2.
The maximum currents induced by the inhibitors at saturating concentrations (I max values) were -25-30% of th ose of the maximum alanine-induced current, indicating that the leak anion conductance of ASCT2 carries about 30% of th e current of the substrate-induced anion conductance, in agreement with previous results obtained for benzylserine (Grewer and Grabsch, 2004) . The inhibitor with the highest apparent affinity was biphenyl serine ester (2c), with a K m of 30 ± 6 μM. This affinity is significantly higher than any previously known ASCT2 inhibitor Grewer and Grabsch, 2004) .
To test whether the inhibitors not only block leak anion current, but also inhibit activity of transported substrates, we applied the compounds in th e presence of alanine (200 μM). As shown in the representative results in Figs. 5C-E, 3c fully inhibited the alanine-induced response and generated leak current block even in the presence of activating substrate (Fig. 5C ).
Compound 5c was evaluated in more detail, as shown in Figs. 5D, E. The apparent K I increased with increasing [alanine], as expected for a co mpetitive mechanism. The K I vs. [alanine] relationship calculated according to eq. 1 (Figure legend 5) , fits well to the experimental data, indicating a competitive inhibition mechanism.
Inhibitor dissociation kinetics. We used a rapid solution exchange protocol to determine the dissociation of the naphtyl ester, 3c. The strategy was to pre-equilibrate the cell with the inhibitor, followed by a rapid step into a solution containing a saturating concentration of Structure-activity analysis of ASCT2 substrates and inhibitors. P revious work on the homologous acidic amino acid transporters (EAATs) showed that bulk of the bound amino acid side chain is an important determinant for the strength of interaction of the ligand with its binding site, as well as for defining substrate or inhibitor properties. To test whether ASCT2 ligand behavior obeys similar principles, we analyzed the apparent affinity of the interaction with the protein as a function of amino acid properties, such as side chain volume and hydrophobicity, as defined by log(P) (Fig. 7 , P = octanol-water partition coefficient). The data suggest that the affinity of activating substrates increases with decreasing side chain volume, as w ell as side chain hydrophobicity. In contrast, the affinity of inhibitors increases with increasing side chain volume and log(P) (Fig. 7) .
Next, we extended the structure-activity analysis to the ability of the compounds to induce or inhibit anion current. As shown in Fig. 8 , compounds with a side chain volume below 110
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Here, we c ombined in-silico docking with a functional assay to gain insight into the mechanisms that govern substrate recognition by the neutral amino acid transporter ASCT2. The docking analysis led to a congeneric series of compounds, which were chemically synthesized and tested with regard to their ability to activate or inhibit the ASCT2-mediated anion conductance, a measure for transport activity. The main new result from this study is that predictors, including side-chain hydrophobicity and volume, allow the classification of compounds into activating substrates, partial substrates, and inactivating inhibitors. The results will be useful to more accurately predict ligand behavior in the ASCT2 binding site. Our results for ligand binding to the highly-homologous neutral amino acid transporter ASCT2 are consistent with these ideas. In particular, the docking results suggest that compounds that are transported by ASCT2 (activate the anion conductance) bind preferentially to the closedloop configuration. In contrast, inhibitors are excluded from the closed-loop configuration due to steric clash, but they bind with significant docking scores to the open-loop configuration.
Mechanism of ligand interaction
Thus, it is likely that ASCT2 inhibitors prevent RL2 closure due to the steric inability of the inhibitor-ASCT2 complex to adopt a closed-loop configuration. Consistent with this model, inhibitor potency, in docking and in the experiment, scales with the volume, as well as the hydrophobicity of the amino acid side chain (Fig. 7) . F or transported substrates, our results suggest that they interact poorly with the open loop configuration, but strongly with the closedloop configuration, thus shifting the equilibrium to the closed-loop form.
It should be noted that for t he inhibitors with the more bulky aromatic substituents, such as fluorenyl and naphtyl, no poses were found, in which the aromatic group associates with the center of RL2. A plausible reason for this behavior is that the side chains are too bulky to fit into simulation results of Glt Ph, in which the open-loop conformation on average showed a higher degree of RL2 opening than the TBOA-bound form (Huang and Tajkhorshid, 2008) . Therefore, it can be speculated that RL2 can adopt varying degrees of opening, depending on the type of bound substrate, ranging from fully closed for the rapidly-transported substrates, to partially closed for the partial substrates, to fully open for the bulkiest inhibitors. S uch a mechanism would not be unprecedented, as in glutamate receptors, which rely on a venus flytrap model for receptor activation by ligand binding (Abele et al., 1999; Armstrong and Gouaux, 2000) , the efficacy of the ligand to induce channel opening depends on the degree of domain closure.
Our results suggest that the compound with the naphtyl substituent (3c) dissociates from its binding site with an apparent rate coefficient of k d = 72 s -1 . Assuming a dissociation constant of
. This rate constant is lower than expected for diffusion-controlled binding. Therefore, it can be hypothesized that binding of bulky inhibitors requires an additional conformational change of the ASCT2 binding site.
Predicting the activating/inhibiting nature of the substrate. One of the main objectives of this study was to be able to develop predictors of ASCT2 substrate behavior. Consistent with results for EAATs, hydrophobic bulk in the side chain aids high affinity interaction with ASCT2, in particular if this bulk is aromatic. S ide chain volume can be used to discriminate between transported substrates and inhibitors (Fig. 8) , with full substrates exhibiting side chain volumes less than 100 interaction, but this bulk needs to be aromatic. As is shown in table 2, compound 1c with the cyclohexyl substituent did not interact with ASCT2. T his indicates that a large, hydrophobic aliphatic group is not sufficient for bi nding, but that aromatic nature of t he side chain is important. This requirement for aromatic nature is not well represented by the docking results, in which 3c is predicted to bind to the open-loop form with a high docking score (table 2) . This is not surprising, as the scoring function only includes a general hydrophobic term in the absence of π-specific interactions (Trott and Olson, 2010) . I n the homology model, only two aromatic residues are in the vicinity of th e binding site for potential π-stacking interaction (F391 and W459), but both of these side chains are too far away from the predicted binding location of the aromatic ring(s). Therefore, the detailed physical description of th e binding site interaction awaits further study.
ASCT2 pharmacology.
Relatively few inhibitors for amino acid transport by ASCT2 have been developed. In one study, benzylserine was found to be a prototypic competitive ASCT2
inhibitor, based on its structural similarity to the glutamate transporter blocker TBOA (Grewer and Grabsch, 2004) . However, benzylserine binds with somewhat low affinity (∼1 mM). In another report, a s eries of a sparagine derivatives was investigated, with aromatic groups linked to the amide nitrogen . While no K i values were given for the compounds, the most potent inhibitor, p-nitrophenyl glutamyl anilide, inhibited 50% of the uptake at about 0.25 mM . Although not knowing the exact K m value of the C6-cell glutamine transporter for glutamine, it can be estimated that the actual K i of t he compound is about 80 μM at 100 μM glutamine. Our most potent inhibitor based on th e biphenyl moiety binds with a 30 μM apparent affinity (table 2), suggesting that this represents the highest affinity inhibitor for ASCT2 known to date, surpassing the previous compound in potency by at least a This article has not been copyedited and formatted. The final version may differ from this version. Interestingly, the study by Esslinger et al. concluded that a H-bond donor in the side chain, in form of the amide N-H group, is important for high affinity interaction. However, in our series of compounds no hydrogen bond donor is present at th is position. This result suggests that the H-bond donor is not required for high affinity interaction of inhibitors with the ASCT2 binding site, but it does not exclude the possibility that the introduction of a H -bond donor to the fluorenyl compound could increase affinity. This possibility may be tested in future experiments.
A significant problem for the development of ASCT2 inhibitors is specificity. For example, aryl-asparagine derivatives have been reported as high affinity inhibitors for glu tamate transporters (Greenfield et al., 2005) . This indicates that the absence of the negatively-charged β-carboxylate group does not abolish interaction with the binding site of EAATs. Consistently, the ASCT2 inhibitors tested here, except benzylserine, also inhibit the glutamate transporter EAAT3 (data not shown). This is an important finding, as it means that cell biological or neurophysiological studies relying on pharmacological inhibition of glutamate transporters have to be evaluated carefully, since many of the known EAAT inhibitors may also inhibit ASCTs, although their ASCT2 action has never been tested. Therefore, effects may be ascribed to inhibition of EAATs that may partially be caused by inhibition of neutral amino acid transporters.
Therefore, it remains a ch allenge to develop high-affinity inhibitors that preferentially bind to ASCTs over EAATs. Pure reliance on hydrophobic bulk in the side chain to achieve high-affinity interaction will not be sufficient to generate selectivity. S pecificity may also be difficult to achieve with respect to other neutral amino acid transporter families. The pharmacology of the System A and System N transporters is not well established, preventing us from commenting on This article has not been copyedited and formatted. The final version may differ from this version. (Segawa et al., 1999) .
Therefore, it is conceivable to assume that aromatic serine esters may also interact with the LAT family of amino acid transporters Side-chain aromaticity is required for high-affinity interaction. These predictions allowed us to develop an inhibitor that binds to ASCT2 with 30 μM apparent affinity, which to our knowledge is currently unsurpassed by other ASCT2 inhibitors. In light of the presumed importance of ASCT2 in glutamine release from proliferating astrocytes, thus potentially contributing to the glutamate-glutamine cycle (Broer and Brookes, 2001) , as well as the well known up-regulation of ASCT2 in many cancers (Fuchs and Bode, 2005) , the development of new ASCT2 inhibitors may lead to compounds of therapeutic value.
Conclusions
